Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide
| العنوان: | Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide |
|---|---|
| المؤلفون: | Anne Clavreul, Frédéric Lagarce, Khaled Messaoudi |
| المساهمون: | Micro et Nanomédecines Biomimétiques (MINT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Univ Angers, Okina |
| المصدر: | Drug Discovery Today Drug Discovery Today, 2015, 20 (6), pp.772-9. ⟨10.1016/j.drudis.2015.02.014⟩ Drug Discovery Today, Elsevier, 2015, 20 (6), pp.772-9. ⟨10.1016/j.drudis.2015.02.014⟩ |
| بيانات النشر: | Elsevier BV, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.CAN]Life Sciences [q-bio]/Cancer, Tumor cells, Biology, Bioinformatics, RNAi Therapeutics, Immune system, [SDV.CAN] Life Sciences [q-bio]/Cancer, RNA interference, Drug Discovery, Biomarkers, Tumor, Temozolomide, medicine, Animals, Humans, Antineoplastic Agents, Alkylating, Pharmacology, Regulation of gene expression, Brain Neoplasms, Mechanism (biology), fungi, Gene Transfer Techniques, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, medicine.disease, 3. Good health, Dacarbazine, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, medicine.drug, Glioblastoma |
| الوصف: | International audience; RNA interference (RNAi) is a strategy of gene regulation that has opened up many opportunities for the treatment of cancers, especially glioblastoma multiforme (GBM). This strategy reduced the expression of many proteins involved in the resistance of these tumors to anticancer drugs, particularly to temozolomide (TMZ). A significant research effort has gone into RNAi delivery and target selection for clinical application of this new discovery in the treatment of GBMs. However, some limitations must be resolved to enhance the safety of RNAi-based therapeutics and to reduce their immune response. In this review, the mechanism of RNAi will be described. Moreover, the opportunities offered by RNAi strategy to reverse the phenotype of these tumor cells as well as prospects and challenges ahead in the RNAi-based therapy will be discussed. |
| وصف الملف: | application/pdf |
| تدمد: | 1359-6446 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf7da3107dc826a7e8de6a937609db00Test https://doi.org/10.1016/j.drudis.2015.02.014Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....bf7da3107dc826a7e8de6a937609db00 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13596446 |
|---|